Comparison · NCT05701007-bfcd8949
Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Undergone Palliative Radiology
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Undergone Palliative Radiology. Trial comparisons, record NCT05701007-bfcd8949. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05701007-bfcd8949
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.279 | 0.249 | 0.311 | wilson | |
| Risk in group 2 | 0.335 | 0.297 | 0.375 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0559 | -0.106 | -0.00614 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.833 | 0.709 | 0.979 | log | |
| Odds ratio, group 1 over group 2 | 0.769 | 0.608 | 0.972 | log | |
| Number needed to treat, for one fewer participant with the outcome on Participants Diagnosed With mCSPC than on Participants Diagnosed With mCRPC | 17.9 | 9.43 | 163 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Participants Diagnosed With mCSPC | Eligible participants with mCSPC and whose data were evaluated retrospectively. | 222 | 795 | OG000 |
| Group 2 | Participants Diagnosed With mCRPC | Eligible participants with mCRPC and whose data were evaluated retrospectively. | 187 | 558 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Undergone Palliative Radiology
- Description
Number of participants with palliative radiology done were reported in this outcome measure. This is a treatment designed to alleviate symptoms caused by advanced cancer, rather than cure the disease. It is commonly used to reduce tumor size or provide relief from pain, bleeding, or obstructions, ultimately enhancing the participant's quality of life. It is especially beneficial for participants with cancers that cannot be cured, offering relief from distressing symptoms such as tumor compression on organs or bones, as well as severe pain. Palliative radiology is analyzed based on procedure code (WF049). Index date for (i) mCSPC participants were defined as date for the first record of mPC (ii) mCRPC participants were defined as date for progression to castration resistant (if =3 months from castration-sensitive treatment initiation \[1st control usually at 3 months\], considered de novo CRPC).
- Time frame
Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
- Population
- Analysis population included all eligible participants whose data were included and observed for evaluation in the study.
Source ClinicalTrials.gov
Trial
- Title
- Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- NCT number
- NCT05701007
- Phases
- Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- abiraterone, enzalutamide, docetaxel, apalutamide, cabazitaxel, Radium-223, Lutetium-177, degarelix, goserelin, leuprorelin, triptorelin
- Lead sponsor
- Pfizer
- Results first posted
- 2026-01-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05701007?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05701007-bfcd8949